This is a cache of https://www.uibk.ac.at/en/pharmazie/pharmakologie/calciumchannelprojects/nadine-ortner/. It is a snapshot of the page at 2025-05-14T17:09:09.152+0200.
Nadine Ortner – Universität Innsbruck

Mag. Nadine J. Ortner, PhD 

Principle Investigator
Email: Nadine.Ortner@uibk.ac.at 
Phone: +43-(0)512-507 - 58815
ORCID: https://orcid.org/0000-0003-3882-3283 
H-index: 14 (Google Scholar); 12 (Web of Science: MVW-4231-2025)

MAIN RESEARCH INTEREST
Neuro(patho)physiology & Molecular Pharmacology of Voltage-Gated Calcium Channels

"I am particularly interested in deciphering the role of voltage-gated Ca2+ channels in brain disorders such as Parkinson’s disease, autism spectrum disorder or epilepsies and their pharmacological modulation as a potential therapeutic intervention. For my studies I employ molecular (cloning, generation of stable cell lines), electrophysiological (heterologous expression systems, brain slices), immunohistochemical and pharmacological methods."

RESEARCH GROUP

FG 3500 Multisystem study of pathogenic CACNA1D variants

Project Ortner: 
Endocrine and neuronal cell dysfunction in Cav1.3AG mice
Research Group
GRADUATE PROGRAM

CavX PhD Program"Calcium channels in excitabel cells"

Selective Cav1.3 inhibition for the treatment of human gain-of-function CACNA1D channelopathies
Graduate Program & Research Network
RESEARCH FUNDING

FWF: The dopaminesystem in a new Cav1.3 Ca2+ channelopathy mouse model of a neurodevelopmental disorder

OeAD: Centralizing available information on disease-associated genetic variants of voltage-gated Ca2+ channels to improve pathogenicity predictions

Research Funding
PhD STUDENTS

Horia HERMENEAN, MSc (started 2024): expected graduation 2028

Title: “Selective Cav1.3 inhibition for the treatment of human gain-of-function CACNA1D channelopathies”
FWF-funded PhD excellence program “CavX – Calcium channels in excitable cells”
New PhD student, start 2025: hearings currently ongoing
MASTER STUDENTS

Philipp PUMBERGER (started 2025): expected graduation December 2025

Title: “Electrophysiological Characterization of Cav1.3 (CACNA1D) L-Type Calcium Channel Variants in the channels’ voltage sensing domain”

Carla NEUWIRTH (started 2025): expected graduation December 2025

Title: “Systematic collection of pathogenic variants of voltage-gated Calcium channels”

SHORT CURRICULUM

Born: April 7, 1987
 
2001 – 2006      
Commercial academy with focus on information technology, Villach, Austria
 
2006 – 2012      
Diploma Program in Molecular Biology, University of Vienna, Austria with special focus on Immunology/Virology, Molecular Medicine and Neuroscience, University of Vienna
Diploma thesis at the Department of Pathophysiology and Allergy Research, Medical University of Vienna, Austria
Supervisor: Prof. Peter Pietschmann
Thesis title: “Osteomacrophages in Cathepsin S Knockout Mice”
 
2012 – 2017      
PhD Program Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Innsbruck, Austria (external member of the FWF-funded excellence PhD program “Molecular Cell Biology and Oncology (MCBO)”)
Supervisor: Prof. Jörg Striessnig
Thesis title: “Pharmacology of Cav1.2 and Cav1.3 L-type Ca2+ channels: implications for the treatment of human brain disorders”
 
2017 – 2019      
Postdoctoral research fellow, Department of Pharmacology and Toxicology, University of Innsbruck, Austria
 
2019 & 2020
Short-term stay-abroad (2 months)
Visiting scientist at the Goethe University of Frankfurt, Germany (Prof. Jochen Roeper)
Retrograde tracing & ex vivo slice electrophysiology of mouse dopamine neurons
 
2019 – present
University assistant, Erika-Cremer habilitation fellowship of the University of Innsbruck, Austria
Group leader “Neuro(patho)physiology & Molecular Pharmacology of Ca2+ channels”

FELLOWSHIPS & THIRD PARTY FUNDING

2025 – 2030       
Research group (Austrian Science Fund, FWF)
Title: Resolving the patient phenotypic spectrum induced by CACNA1D (Cav1.3) missense variants using a multisystem approach
Project Ortner: Endocrine and neuronal cell dysfunction in Cav1.3AG mice
Amount: 303,488.1 € (total: 1,642,693.1 €)
Contribution: Coordinator and PI of one subproject (5 subprojects in total)
 
2024 – 2025      
Mobility grant in cooperation with Czech Republic (OeAD)
Title: Centralizing available information on disease-associated genetic variants of voltage-gated Ca2+ channels to improve pathogenicity prediction
Amount: 7,920 €
Contribution: PI of the Austrian project (Norbert Weiss, Charles University, Prague)
 
2023 – 2027       
doc.funds PhD program (Austrian Science Fund, FWF)
Title: CavX – Calcium channels in excitable cells
Project Ortner: Selective Cav1.3 inhibition for the treatment of human gain-of-function CACNA1D channelopathies
Amount: 196,000 € (total: 1,441,421 €)
Contribution: PI of one subproject (7 subprojects)
 
2021 – 2026      
Stand-alone project (Austrian Science Fund, FWF)
Title: The dopamine system in a new Cav1.3 Ca2+ channelopathy mouse model of a neurodevelopmental disorder
Amount: 165,781 €
 
2019 – 2024      
Erika-Cremer habilitation fellowship of the University of Innsbruck
Amount: 4-year full-time position
awarded annually to one female researcher of the University of Innsbruck to promote scientific excellence and her further scientific career
 
2018                    
Stand-alone project (Tyrolean Science Fund, TWF)
Title: Subtype-selective inhibitors of voltage-gated Ca2+ channels to treat CNS disorders
Amount: 18,100 €
 
2017                    
Jubiläumsfonds (University of Innsbruck & Medical University of Innsbruck for sponsorship of scientific cooperation projects; with Enrica Paradiso)
Title: Neuroanatomical characterization of a newly established transgenic mouse model of autism spectrum disorder
Amount: 10,010 €

RESEARCH ACHIEVEMENTS (Invited talks, Symposia & Awards)

2025
  • Upcoming: Invited talk at the Regional Physiology Meeting 2025 (RPM2025), 24-26 September 2025, Ljubljana, Slovenia. Title: “Preclinical models for a rare Cav1.3 channelopathy: insights into the pathophysiology and therapeutic options.”
  • Upcoming: Accepted symposium (Organizer & Talk) at the Austrian Neuroscience Association Meeting 2025, 8-10 September 2025, Institute of Science and Technology Austria (ISTA), Klosterneuburg, Austria; Title: “Calcium channelopathies: beyond the ion-conducting pore”
  • Upcoming: Invited talk at the Ion Channel Modulation Symposium ICMS 2025, 25-26 June 2025, Clare College, Cambdridge, UK; Title: “Pathogenic CACNA1D (CaV1.3) variants - linking biophysical changes to pathophysiology”
  • Upcoming: Chair: The 5th European Calcium Channel Conference (ECCC), Alpbach, Austria, 26-30 May 2025; Title of Symposium: “Ion channel regulation in disease”
 
2024
  • Invited talk at the Pre-Congress Symposium “Ion Channels in Health and Disease” at the Annual Meeting of the German Physiological Society, Austrian Physiological Society and Life Sciences Switzerland Physiology, 18 September 2024, Vienna, Austria; Title: “Genetic variants of CACNA1D (CaV1.3) in neurodevelopmental disorders: preclinical models and clinical implications” 
  • Accepted symposium (Organizer & Chair) at the Annual Meeting of the German Physiological Society, Austrian Physiological Society and Life Sciences Switzerland Physiology, 18 September 2024, Vienna, Austria; Title: “Calcium channelopathies: from molecular mechanisms to clinical diversity”
  • Invited talk at the 33rd Ion Channels Meeting of the Association Canaux Ioniques, 8-11 September 2024, Sète, France, Title: “Cav1.3 variants: from molecular mechanisms to therapeutic approaches”
 
2023         
  • Heribert Konzett Award of the Austrian Pharmacological Society (APHAR) awarded annually to honour outstanding achievements of young scientists who are already conducting independent research in the field of experimental and clinical pharmacology
  • Invited talk at the 19th World Congress of Basic & Clinical Pharmacology (WCP2023), 2-7 July 2023, Glasgow, Scotland; Title: “Cav1.3 calcium channel dysfunction in neurodevelopmental disease”
 
2019         
  • Poster & Travel Award at the FASEB The Ion Channel Regulation Conference: From Molecules to Disease, 7-12 July 2019, Lisbon, Portugal. Title: “A human autism-associated CACNA1D gain-of-function mutation is disease-causing in a novel mouse model of neurodevelopmental disorder”
 
2017         
  • Price by the Principality of Liechtenstein for scientific research at the University of Innsbruck - Awarded annually to recognize outstanding scientific research
  • ALUMNI-I-MED Talk Prize at the PhD Life Science Meeting Innsbruck, 2017
 
2015         
  • Award: PHOENIX Pharmazie Wissenschaftspreis awarded to Jörg Striessnig for the publication „Ortner et al., 2014: Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators”, Nat Commun. 2014Jun 19;5:3897”
  • Best paper Award 2015 of the PhD program MCBO of the Innsbruck Universities

PEER REVIEW ACTIVITIES / EDITORIAL ASSIGNMENTS

Ad hoc referee for journals such as Hypertension, Frontiers in Pharmacology, Frontiers in Neuroscience, Channels, Genetics in Medicine, Behavioral Brain Research.
Associate Editor for Channels (Austin), a peer-reviewed and fully open access journal for all types of research related to ion channels, transporters and exchangers (https://www.tandfonline.com/journals/kchl20/about-this-journal#journal-metrics)

MEETING / CONFERENCE ORGANIZATION

 
2025       
  • Neurodays 2025 (https://www.i-med.ac.at/neurodays/): Co-organization. A forum for the neuroscience community in Innsbruck, which aims to promote the exchange between researchers from basic to clinical neuroscience – with a special focus on early career scientists     
  • The 5th European Calcium Channel Conference (ECCC), Alpbach, Austria, 2025: Co-organization (https://calciumchannel.eu/). This conference is held every three years in Alpbach and attracts experts in the field of Ca2+ channel research from all over the world.

THIRD MISSION / PUBLIC OUTREACH

2024         
  • Public lecture for “Wiener Volkshochschule (VHS)”:  „Kalziumkanäle außer Kontrolle – Folgen und Therapieentwicklung“
  • Joining the patient-led initiative The Voltage-Gated Calcium Channel Collective “The VGCCC” which aims to raise awareness, identify affected patients and promote collaboration across all voltage-gated Ca2+ channelopathies.
 
2017       
  • Teaching Neuroscience in Schools & Youth centres in association with “Junge Uni Innsbruck”
 
2016 – 2017       
  • Pint of Science Festival Austria & WissensDurst Festival Austria Co-organization
  • To promote science communication and raise awareness for scientific research in the general public
 
2016 – 2018       
  • Interactive stations on the topic “Neuroscience” for students at events such as “Lange Nacht der Forschung” or “Brain Day” as part of the Special Research Area (“Spezialforschungsbereich”) SFB-f44 Cell signalling in chronic CNS disorders https://www.uibk.ac.at/projects/hirnforschung/

PATIENT ADVOCACY GROUPS

The Voltage-Gated Calcium Channel Collective (“The VGCCC”) is a collaboration of registered non-profit organizations (CACNA1A Foundation, Timothy Syndrome Alliance CACNA1C, CACNA1E International, CACNA1H Alliance) and Patient Advocacy Groups (CACNA1B, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S). It unites caregivers, individuals, researchers, and clinicians focused on all ten 10 isoforms of voltage-gated Ca2+ genes and associated Ca2+ channelopathies with the aim to build a sustainable global partnership between patient families, clinicians, and researchers to facilitate information exchange, drive research, and raise awareness for these rare channelopathies.

Our mission & vision:
Creating an efficient feedback loop among families, clinicians and basic researchers to exchange “real-life” clinical information and preclinical data, to unravel disease-underlying mechanisms as well as develop and test potential therapeutic interventions in a patient-centered manner.
 
 
Patient Advocacy Groups

 

ORIGINAL PAPERS IN PEER-REVIEWED JOURNALS

  1.  Karagulyan, N., A. Thirumalai, S. Michanski, Y. Qi, Q. Fang, H. Wang, N. J. Ortner, J. Striessnig, N. Strenzke, C. Wichmann, Y. Hua and T. Moser. 2025. Gating of hair cell Ca2+ channels governs the activity of cochlear neurons. Sci Adv. (accepted). Preprint: https://www.biorxiv.org/content/10.1101/2025.01.23.634330v1).
  2. Haddad, S., C. Ablinger, R. Stanika, M. Hessenberger, M. Campiglio, N. J. Ortner, P. Tuluc, and G. J. Obermair. 2025. A biallelic mutation in CACNA2D2 associated with developmental and epileptic encephalopathy affects calcium channel-dependent as well as synaptic functions of α2δ-2. J Neurochem. 169(1):e16197, doi: 10.1111/jnc.16197, https://www.ncbi.nlm.nih.gov/pubmed/39161180.
  3. Torök, F., S. Salamon, N. J. Ortner, M. L. Fernandez-Quintero, J. Matthes, and J. Striessnig. 2025. Inactivation induced by pathogenic Cav1.3 L-type Ca2+-channel variants enhances sensitivity for dihydropyridine Ca2+ channel blockers. Br J Pharmacol. 182(1):181-197, doi: 10.1111/bph.17357, https://www.ncbi.nlm.nih.gov/pubmed/39370994.
  4. Tang, X., N. J. Ortner, Y. V. Nikonishyna, M. L. Fernandez-Quintero, J. Kokot, J. Striessnig, and K. R. Liedl. 2024. Pathogenicity of de novo CACNA1D Ca2+ channel variants predicted from sequence co-variation. Eur J Hum Genet. 32(9):1065-1073, doi: 10.1038/s41431-024-01594-y, https://www.ncbi.nlm.nih.gov/pubmed/38553610.
  5. Theiner, T., N. J. Ortner, H. Oberacher, G. Stojanovic, P. Tuluc, and J. Striessnig. 2024. Novel protocol for multiple-dose oral administration of the L-type Ca2+ channel blocker isradipine in mice: A dose-finding pharmacokinetic study. Channels (Austin). 18(1):2335469, doi: 10.1080/19336950.2024.2335469, https://www.ncbi.nlm.nih.gov/pubmed/38564754.
  6. Dannenberg, F., A. Von Moers, P. Bittigau, J. Lange, S. Wiegand, F. Torok, G. Stolting, J. Striessnig, M. M. Motazacker, M. F. Broekema, M. Schuelke, A. M. Kaindl, U. I. Scholl, and N. J. Ortner. 2024. A Novel De Novo Gain-of-Function CACNA1D Variant in Neurodevelopmental Disease With Congenital Tremor, Seizures, and Hypotonia. Neurol Genet. 10(5):e200186, doi: 10.1212/NXG.0000000000200186, https://www.ncbi.nlm.nih.gov/pubmed/39246741.
  7. Torök, F., K. Tezcan, L. Filippini, M. L. Fernandez-Quintero, L. Zanetti, K. R. Liedl, R. S. Drexel, J. Striessnig, and N. J. Ortner*. 2023. Germline de novo variant F747S extends the phenotypic spectrum of CACNA1D Ca2+ channelopathies. Hum Mol Genet. 32(5):847-859, doi: 10.1093/hmg/ddac248, https://www.ncbi.nlm.nih.gov/pubmed/36208199.
  8. Ortner, N. J.#, A. Sah, E. Paradiso, J. Shin, S. Stojanovic, N. Hammer, M. Haritonova, N. T. Hofer, A. Marcantoni, L. Guarina, P. Tuluc, T. Theiner, F. Pitterl, K. Ebner, H. Oberacher, E. Carbone, N. Stefanova, F. Ferraguti, N. Singewald, J. Roeper, and J. Striessnig. 2023. The human channel gating-modifying A749G CACNA1D (Cav1.3) variant induces a neurodevelopmental syndrome-like phenotype in mice. JCI Insight. 8(20), doi: 10.1172/jci.insight.162100, https://www.ncbi.nlm.nih.gov/pubmed/37698939.
  9. Nikonishyna, Y. V., N. J. Ortner, T. Kaserer, J. Hoffmann, S. Biskup, M. Dafotakis, K. Reetz, J. B. Schulz, J. Striessnig, and M. F. Dohrn. 2022. Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia. Mov Disord. 37(2):401-404, doi: 10.1002/mds.28835, https://www.ncbi.nlm.nih.gov/pubmed/34647648.
  10. El Ghaleb, Y., N. J. Ortner, W. Posch, M. L. Fernandez-Quintero, W. E. Tuinte, S. Monteleone, H. J. Draheim, K. R. Liedl, D. Wilflingseder, J. Striessnig, P. Tuluc, B. E. Flucher, and M. Campiglio. 2022. Calcium current modulation by the gamma1 subunit depends on alternative splicing of CaV1.1. J Gen Physiol. 154(9), doi: 10.1085/jgp.202113028, https://www.ncbi.nlm.nih.gov/pubmed/35349630.
  11. Siller, A., N. T. Hofer, G. Tomagra, N. Burkert, S. Hess, J. Benkert, A. Gaifullina, D. Spaich, J. Duda, C. Poetschke, K. Vilusic, E. M. Fritz, T. Schneider, P. Kloppenburg, B. Liss, V. Carabelli, E. Carbone, N. J. Ortner*, and J. Striessnig. 2022. β2-subunit alternative splicing stabilizes Cav2.3 Ca2+ channel activity during continuous midbrain dopamine neuron-like activity. Elife. 11, doi: 10.7554/eLife.67464, https://www.ncbi.nlm.nih.gov/pubmed/35792082.
  12. Ortner, N. J.*, A. Pinggera, N. T. Hofer, A. Siller, N. Brandt, A. Raffeiner, K. Vilusic, I. Lang, K. Blum, G. J. Obermair, E. Stefan, J. Engel, and J. Striessnig. 2020. RBP2 stabilizes slow Cav1.3 Ca2+ channel inactivation properties of cochlear inner hair cells. Pflugers Arch. 472(1):3-25, doi: 10.1007/s00424-019-02338-4, https://www.ncbi.nlm.nih.gov/pubmed/31848688.
  13. Hofer, N. T., P. Tuluc, N. J. Ortner, Y. V. Nikonishyna, M. L. Fernandes-Quintero, K. R. Liedl, B. E. Flucher, H. Cox, and J. Striessnig. 2020. Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder. Mol Autism. 11(1):4, doi: 10.1186/s13229-019-0310-4, https://www.ncbi.nlm.nih.gov/pubmed/31921405.
  14. Campiglio, M., P. Coste de Bagneaux, N. J. Ortner, P. Tuluc, F. Van Petegem, and B. E. Flucher. 2018. STAC proteins associate to the IQ domain of Ca(V)1.2 and inhibit calcium-dependent inactivation. Proc Natl Acad Sci U S A. 115(6):1376-1381, doi: 10.1073/pnas.1715997115, https://www.ncbi.nlm.nih.gov/pubmed/29363593.
  15. Ortner, N. J., G. Bock, A. Dougalis, M. Kharitonova, J. Duda, S. Hess, P. Tuluc, T. Pomberger, N. Stefanova, F. Pitterl, T. Ciossek, H. Oberacher, H. J. Draheim, P. Kloppenburg, B. Liss, and J. Striessnig. 2017. Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease. J Neurosci. 37(28):6761-6777, doi: 10.1523/JNEUROSCI.2946-16.2017, https://www.ncbi.nlm.nih.gov/pubmed/28592699.
  16. Kaur, G., A. Pinggera, N. J. Ortner, A. Lieb, M. J. Sinnegger-Brauns, V. Yarov-Yarovoy, G. J. Obermair, B. E. Flucher, and J. Striessnig. 2015. A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated Cav1.2 Calcium Channel Function. J Biol Chem. 290(34):21086-21100, doi: 10.1074/jbc.M115.645671, https://www.ncbi.nlm.nih.gov/pubmed/26100638.
  17. Ortner, N. J., G. Bock, D. H. Vandael, R. Mauersberger, H. J. Draheim, R. Gust, E. Carbone, P. Tuluc, and J. Striessnig. 2014. Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nat Commun. 5:3897, doi: 10.1038/ncomms4897, https://www.ncbi.nlm.nih.gov/pubmed/24941892.
  18. Lieb, A., N. Ortner, and J. Striessnig. 2014. C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca2+ channels. Biophys J. 106(7):1467-1475, doi: 10.1016/j.bpj.2014.02.017, https://www.ncbi.nlm.nih.gov/pubmed/24703308.
 

 For publications in Pubmed click here

PEER-REVIEWED REVIEW ARTICLES

  1. Ortner, N. J#. 2024. Is Cav1.3 a feasible therapeutic target for a rare neurodevelopmental disorder? Expert Opin Ther Targets. 28(12):1021-1025, doi: 10.1080/14728222.2024.2442428, https://www.ncbi.nlm.nih.gov/pubmed/39670814.
  2. Filippini, L., N. J. Ortner, T. Kaserer, and J. Striessnig. 2023. Cav1.3-selective inhibitors of voltage-gated L-type Ca2+ channels: Fact or (still) fiction? Br J Pharmacol. 180(10):1289-1303, doi: 10.1111/bph.16060, https://www.ncbi.nlm.nih.gov/pubmed/36788128.
  3. Ortner, N. J#. 2021. Voltage-Gated Ca2+ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease? Front Synaptic Neurosci. 13:636103, doi: 10.3389/fnsyn.2021.636103, https://www.ncbi.nlm.nih.gov/pubmed/33716705.
  4. Ortner, N. J.*, T. Kaserer, J. N. Copeland, and J. Striessnig. 2020. De novo CACNA1D Ca2+ channelopathies: clinical phenotypes and molecular mechanism. Pflugers Arch. 472(7):755-773, doi: 10.1007/s00424-020-02418-w, https://www.ncbi.nlm.nih.gov/pubmed/32583268.
  5. Ortner, N. J., and J. Striessnig. 2016. L-type calcium channels as drug targets in CNS disorders. Channels (Austin). 10(1):7-13, doi: 10.1080/19336950.2015.1048936, https://www.ncbi.nlm.nih.gov/pubmed/26039257.
  6. Striessnig, J., N. J. Ortner, and A. Pinggera. 2015. Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets? Curr Mol Pharmacol. 8(2):110-122, doi: 10.2174/1874467208666150507105845, https://www.ncbi.nlm.nih.gov/pubmed/25966690.
Book chapters
  1. Ortner, N. J. # 2023. CACNA1D-Related Channelopathies: From Hypertension to Autism. Handb Exp Pharmacol. 279:183-225, doi: 10.1007/164_2022_626, https://www.ncbi.nlm.nih.gov/pubmed/36592224.
  2. Striessnig, J., Ortner, N.J. (2021). Ca2+ Channel Blockers. In: Offermanns, S., Rosenthal, W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-030-57401-7_34.
In revision

M. Tisch, S. M. Geisler, Q. Schlemmer, M. Lechner, E. Gabassi, J. Ulz, M. Suarez Cubero, L. De Gaetano, A. Spathopoulou, J. Striessnig, N. J. Ortner, K. Günther, P.Tuluc, F. Edenhofer. Aberrant Ca2+ signaling and neuronal activity in the L271H CACNA1D (Cav1.3) iPSC model of neurodevelopmental disease. In revision in Molecular Psychiatry

PRESS REPORTS

05/2025  Research group investigates gene mutations responsible for rare diseases

12/2024  FWF: Neue Forschungsgruppen starten (Forschungsgruppe „Multisystemische Studie von pathogenen CACNA1D-Varianten“)

09/2023  Von der Freude abzuschließen: Nadine ORTNER im Portrait

03/2023  Lebenswichtige Kalziumkanäle gemeinsam erforschen 

06/2023  Kontrollverlust mit Folgen 

03/2018  Liechtenstein-Preis zum 35. Mal verliehen 

02/2018  Gemeinsame Forschungsarbeit in den Neurowissenschaften wird gefördert 

11/2015  PHOENIX Preis 2015: Wissenschaftspreis für die AG Jörg STRIESSNIG

MEMBERSHIPS

AUSTRIAN NEUROSCIENCE ASSOCIATION (ANA)

AUSTRIAN PHARMACOLOGICAL SOCIETY (APHAR)

BIOPHYSICAL SOCIETY

 

 

Nach oben scrollen